PolarityTE, Inc. (PTE): Price and Financial Metrics


PolarityTE, Inc. (PTE): $0.72

0.00 (-0.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PTE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

PTE POWR Grades


  • Sentiment is the dimension where PTE ranks best; there it ranks ahead of 97.08% of US stocks.
  • PTE's strongest trending metric is Stability; it's been moving up over the last 100 days.
  • PTE ranks lowest in Stability; there it ranks in the 10th percentile.

PTE Stock Summary

  • The ratio of debt to operating expenses for Polarityte Inc is higher than it is for about merely 5.76% of US stocks.
  • With a year-over-year growth in debt of -96.01%, Polarityte Inc's debt growth rate surpasses just 1.9% of about US stocks.
  • In terms of volatility of its share price, PTE is more volatile than 91.23% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Polarityte Inc, a group of peers worth examining would be FUV, OM, AMWL, ASXC, and NTRA.
  • Visit PTE's SEC page to see the company's official filings. To visit the company's web site, go to www.polarityte.com.

PTE Valuation Summary

  • PTE's price/earnings ratio is -1.5; this is 104.11% lower than that of the median Healthcare stock.
  • Over the past 212 months, PTE's EV/EBIT ratio has gone up 10.4.
  • PTE's price/earnings ratio has moved up 6.5 over the prior 212 months.

Below are key valuation metrics over time for PTE.

Stock Date P/S P/B P/E EV/EBIT
PTE 2021-08-31 4.1 2.1 -1.5 -0.7
PTE 2021-08-30 4.1 2.2 -1.5 -0.7
PTE 2021-08-27 4.2 2.2 -1.6 -0.7
PTE 2021-08-26 4.2 2.2 -1.6 -0.7
PTE 2021-08-25 4.4 2.3 -1.6 -0.8
PTE 2021-08-24 4.4 2.3 -1.6 -0.8

PTE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PTE has a Quality Grade of C, ranking ahead of 34.18% of graded US stocks.
  • PTE's asset turnover comes in at 0.289 -- ranking 158th of 682 Pharmaceutical Products stocks.
  • BTX, RMTI, and KPTI are the stocks whose asset turnover ratios are most correlated with PTE.

The table below shows PTE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.289 0.569 -2.653
2021-03-31 0.276 0.563 -2.847
2020-12-31 0.194 0.563 -2.485
2020-09-30 0.148 0.599 -2.425
2020-06-30 0.100 0.587 -2.675
2020-03-31 0.075 0.567 -2.684

PTE Price Target

For more insight on analysts targets of PTE, see our PTE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.25 Average Broker Recommendation 1.67 (Moderate Buy)

PTE Stock Price Chart Interactive Chart >

Price chart for PTE

PTE Price/Volume Stats

Current price $0.72 52-week high $1.99
Prev. close $0.72 52-week low $0.38
Day low $0.64 Volume 11,429,172
Day high $0.83 Avg. volume 3,321,018
50-day MA $0.53 Dividend yield N/A
200-day MA $0.77 Market Cap 58.83M

PolarityTE, Inc. (PTE) Company Bio


PolarityTE, Inc. operates as a translational regenerative medicine company. The Company develops functionally polarized human tissues to improve clinical medicine and biomedical research. PolarityTE offers its services in the United States.


PTE Latest News Stream


Event/Time News Detail
Loading, please wait...

PTE Latest Social Stream


Loading social stream, please wait...

View Full PTE Social Stream

Latest PTE News From Around the Web

Below are the latest news stories about Polarityte Inc that investors may wish to consider to help them evaluate PTE as an investment opportunity.

PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application

PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its complete response to the U.S. Food and Drug Administration's (FDA) clinical hold correspondence regarding its Investigational New Drug (IND) Application for SkinTE® with a proposed indication for chronic cutaneous ulcers. As previously disclosed, the primary hold issues are certain Chemistry, Manufacturing, and Control (CMC) items, including t

Yahoo | December 20, 2021

POLARITYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, December 02, 2021--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE) on behalf of long-term stockholders following a class action complaint that was filed against PolarityTE on September 24, 2021. Our investigation concerns whether the board of directors of PolarityTE have breached their fiduciary duties to the company.

Yahoo | December 2, 2021

Last Few Hours to Actively Participate in PolarityTE, Inc. Class Action: Bronstein, Gewirtz & Grossman, LLC

NEW YORK, November 23, 2021--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/

Yahoo | November 23, 2021

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 23, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PolarityTE, Inc. ("PolarityTE" or "the Company") (NASDAQ:PTE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

Yahoo | November 23, 2021

POLARITYTE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all persons and entities who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the “Class Period”)

Yahoo | November 23, 2021

Read More 'PTE' Stories Here

PTE Price Returns

1-mo 84.62%
3-mo 30.65%
6-mo -8.99%
1-year N/A
3-year -95.69%
5-year -79.31%
YTD 22.66%
2021 -13.68%
2020 -73.85%
2019 -80.73%
2018 -41.88%
2017 616.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7841 seconds.